Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Fransson AS, Leskinen MJ, Zeke M, Huttunen T, Ginman C; Investigators of the Scandinavian Prostate Cancer Study No. 13. Kellokumpu-Lehtinen PL, et al. Eur Urol. 2019 Dec;76(6):823-830. doi: 10.1016/j.eururo.2019.08.010. Epub 2019 Aug 20. Eur Urol. 2019. PMID: 31443961 Clinical Trial.
Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial.
Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Marttila T, Seke M, Taalikka M, Ginman C; SPCG-13. Kellokumpu-Lehtinen PL, et al. Prostate Cancer Prostatic Dis. 2012 Sep;15(3):303-7. doi: 10.1038/pcan.2012.13. Prostate Cancer Prostatic Dis. 2012. PMID: 22546837 Clinical Trial.
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellén E, Franzén L, Nilsson P. Widmark A, et al. Lancet. 2019 Aug 3;394(10196):385-395. doi: 10.1016/S0140-6736(19)31131-6. Epub 2019 Jun 18. Lancet. 2019. PMID: 31227373 Clinical Trial.
Corrigendum re "Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial" [Eur Urol 2019;76:823-30].
Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Fransson AF, Leskinen MJ, Zeke M, Huttunen T, Ginman C; Investigators of the Scandinavian Prostate Cancer Study No. 13. Kellokumpu-Lehtinen PL, et al. Eur Urol. 2020 Dec;78(6):e241-e242. doi: 10.1016/j.eururo.2020.08.035. Epub 2020 Sep 4. Eur Urol. 2020. PMID: 32893063 No abstract available.
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P, Nilsson P, Gunnlaugsson A, Beckman L, Tavelin B, Norman D, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Zackrisson B, Kjellén E, Franzén L, Widmark A. Fransson P, et al. Lancet Oncol. 2021 Feb;22(2):235-245. doi: 10.1016/S1470-2045(20)30581-7. Epub 2021 Jan 11. Lancet Oncol. 2021. PMID: 33444529 Clinical Trial.
Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study.
Lehtonen M, Sormunen J, Hjälm-Eriksson M, Thellenberg-Karlsson C, Huttunen T, Ginman C, Kellokumpu-Lehtinen PL; Investigators of the Scandinavian Prostate Cancer Group Study No 13. Lehtonen M, et al. Anticancer Res. 2022 Jan;42(1):87-92. doi: 10.21873/anticanres.15460. Anticancer Res. 2022. PMID: 34969712 Clinical Trial.
The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease.
Bratt O, Carlsson S, Fransson P, Thellenberg Karlsson C, Stranne J, Kindblom J; Swedish National Prostate Cancer Guidelines Group. Bratt O, et al. Among authors: thellenberg karlsson c. Scand J Urol. 2022 Aug;56(4):265-273. doi: 10.1080/21681805.2022.2094462. Epub 2022 Jul 11. Scand J Urol. 2022. PMID: 35811480
Characteristics of Patients in SPCG-15-A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer.
Gongora M, Stranne J, Johansson E, Bottai M, Thellenberg Karlsson C, Brasso K, Hansen S, Jakobsen H, Jäderling F, Lindberg H, Lilleby W, Meidahl Petersen P, Mirtti T, Olsson M, Rannikko A, Røder MA, Henrik Vincent P, Akre O. Gongora M, et al. Among authors: thellenberg karlsson c. Eur Urol Open Sci. 2022 May 26;41:63-73. doi: 10.1016/j.euros.2022.04.013. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35813256 Free PMC article.
38 results